{
    "nctId": "NCT05806060",
    "briefTitle": "Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "Precise Treatment for BLIS Subtype of Triple-negative Breast Cancer in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple-Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 192,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ECOG Performance Status of 0-1\n* Expected lifetime of not less than three months\n* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) with BLIS subtype\n* Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection\n* Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer\n* At least one measurable or non-measurable lesion according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), which didn't receive radiation therapy\n* The functions of major organs are basically normal\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm\n* Have the cognitive ability to understand the protocol and be willing to participate and to be followed up\n\nExclusion Criteria:\n\n* Symptomatic, untreated, or actively progressing CNS metastases\n* Significant cardiovascular disease\n* Adverse reactions of Grade \u22651 that are still continuing due to previous treatments. Exceptions are those of hair loss or which researchers take it as exception\n* Major surgery was performed within 3 weeks of the first course of trial treatment (except for minor outpatient surgery, such as placement of vascular access)\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study\n* Other malignancies within 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma\n* Inability to swallow, chronic diarrhea and intestinal obstruction, there are multiple factors that affect the use and absorption of drugs\n* Presence of third-space fluid accumulation that cannot be controlled by drainage or other methods (such as excessive pleural fluid and ascites)\n* Participated in clinical trials of other antitumor drugs within 4 weeks before first taking the investigational drug\n* Long-term unhealing wound or incomplete healing of fracture\n* Patients with known active HBV or HCV infection or hepatitis B DNA\u2265500, or chronic phase with abnormal liver function\n* Allergic constitution, or known allergic history of the drug components of this trial; Or allergic to other monoclonal antibodies\n* Patients with a history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding within the past 6 months, such as esophageal varicose veins with bleeding risk, locally active ulcer lesions, stool occult blood \u2265 (++), were not allowed to enter the group; If there is occult blood in the stool (+), gastroscopy is required\n* Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 28 days before participating in this trial\n* Urine protein \u22652+ and 24h urine protein quantitative \\> 1.0 g\n* Patients suffering from hypertension and unable to reach the normal range after antihypertensive drug treatment (systolic blood pressure \\>140mmHg, diastolic blood pressure \\>90mmHg)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}